Preparation, characterization, and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 1141-1154

  Wang, Mengshu ^a   Zhang, Yong ^a   Feng, Jiao ^a   Gu, Tiejun ^a   Dong, Qingguang ^a   Yang, Xu ^b   Sun, Yanan ^a   Wu, Yongge ^a   Chen, Yan ^a   Kong, Wei ^a  

^a JILIN UNIVERSITY   (China)

^b BCHT Biopharm Co Ltd   (China)

Author keywords

Chitosan; Intestinal absorption; PLGA

Indexed keywords

CAVEOLIN; CHITOSAN POLYGLACTIN NANOPARTICLE; EXENDIN 4; NANOMATERIAL; NANOPARTICLE; POLYGLACTIN NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL TRANSPORT; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DEACETYLATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TRANSPORT; ENDOCYTOSIS; FLOW CYTOMETRY; MDCK CELL; MOLECULAR WEIGHT; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; RAT; TOXICITY TESTING; ZETA POTENTIAL;

CHITOSAN; INTESTINAL ABSORPTION; PLGA;

AMILORIDE; ANIMALS; CELL SURVIVAL; CHITOSAN; CHLORPROMAZINE; DOGS; DRUG CARRIERS; INTESTINAL ABSORPTION; LACTIC ACID; MADIN DARBY CANINE KIDNEY CELLS; MALE; MODELS, BIOLOGICAL; NANOPARTICLES; PARTICLE SIZE; PEPTIDES; POLYGLYCOLIC ACID; RATS; RATS, WISTAR; SPECTROMETRY, FLUORESCENCE; VENOMS;

EID: 84875302500     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S41457     Document Type: Article

References (38)

1. Li X, Li L, Wang X, Ren Y, Zhou T, Lu W. Application of model-based methods to characterize exenatide-loaded double-walled microspheres: in vivo release, pharmacokinetic/pharmacodynamic model, and in vitro and in vivo correlation. J Pharm Sci. 2012;101(10):3946-3961.
2. Mahato RI, Narang AS, Thoma L, Miller DD. Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst. 2003;20(2-3):153-214.
3. Hamman JH, Enslin GM, Kotzé AF. Oral delivery of peptide drugs: barriers and developments. Bio Drugs. 2005;19(3):165-177.
4. Wang M, Sun B, Feng J, et al. Investigation of transport mechanism of exendin-4 across Madin Darby canine kidney cell monolayers. Biol Pharm Bull. 2012;35(5):745-752.
5. Gedulin BR, Smith PA, Jodka CM, et al. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. Int J Pharm. 2008;356(1-2):231-238.
6. Jin CH, Chae SY, Son S, et al. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice. J Control Release. 2009;133(3): 172-177.
7. Gao M, Jin Y, Tong Y, Tian H, Gao X, Yao W. A site-specific PEGylated analog of exendin-4 with improved pharmacokinetics and pharmacodynamics in vivo. J Pharm Pharmacol. 2012;64(11):1646-1653.
8. Kwon KC, Nityanandam R, New JS, Daniell H. Oral delivery of bioencapsulated exendin-4 expressed in chloroplasts lowers blood glucose level in mice and stimulates insulin secretion in beta-TC6 cells. Plant Biotechnol J. 2013;11(1):77-86.
9. Nguyen HN, Wey SP, Juang JH, et al. The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo. Biomaterials. 2011;32(10):2673-2682.
10. Bivas-Benita M, Romeijn S, Junginger HE, Borchard G. PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium. Eur J Pharm Biopharm. 2004;58(1):1-6.
11. Tahara K, Furukawa S, Yamamoto H, Kawashima Y. Hybrid-modified poly(D,L-lactide-co-glycolide) nanospheres for a novel cellular drug delivery system. Int J Pharm. 2010;392(1-2):311-313.
12. Yang R, Shim WS, Cui FD, et al. Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor. Int J Pharm. 2009;371(1-2):142-147.
13. Yuan X, Shah BA, Kotadia NK, Li J, Gu H, Wu Z. The development and mechanism studies of cationic chitosan-modified biodegradable PLGA nanoparticles for efficient siRNA drug delivery. Pharm Res. 2010;27(7):1285-1295.
14. Schipper NG, Olsson S, Hoogstraate JA, deBoer AG, Vårum KM, Artursson P. Chitosans as absorption enhancers for poorly absorbable drugs 2: mechanism of absorption enhancement. Pharm Res. 1997; 14(7):923-929.
15. Ward PD, Tippin TK, Thakker DR. Enhancing paracellular permeability by modulating epithelial tight junctions. Pharm Sci Technolo Today. 2000;3(10):346-358.
16. Tahara K, Sakai T, Yamamoto H, Takeuchi H, Hirashima N, Kawashima Y. Improved cellular uptake of chitosan-modified PLGA nanospheres by A549 cells. Int J Pharm. 2009;382(1-2):198-204.
17. Tahara K, Sakai T, Yamamoto H, Takeuchi H, Kawashima Y. Establishing chitosan coated PLGA nanosphere platform loaded with wide variety of nucleic acid by complexation with cationic compound for gene delivery. Int J Pharm. 2008;354(1-2):210-216.
18. Chakravarthi SS, Robinson DH. Enhanced cellular association of paclitaxel delivered in chitosan-PLGA particles. Int J Pharm. 2011;409(1-2):111-120.
19. Murugeshu A, Astete C, Leonardi C, Morgan T, Sabliov CM. Chitosan/PLGA particles for controlled release of alpha-tocopherol in the GI tract via oral administration. Nanomedicine (Lond). 2011;6(9):1513-1528.
20. Slütter B, Bal S, Keijzer C, et al. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Vaccine. 2010;28(38):6282-6291.
21. Zhang X, Sun M, Zheng A, Cao D, Bi Y, Sun J. Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration. Eur J Pharm Sci. 2012;45(5):632-638.
22. Ungaro F, d'Angelo I, Coletta C, et al. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J Control Release. 2012;157(1):149-159.
23. Nafee N, Taetz S, Schneider M, Schaefer UF, Lehr CM. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine. 2007;3(3):173-183.
24. Gaumet M, Gurny R, Delie F. Interaction of biodegradable nanoparticles with intestinal cells: the effect of surface hydrophilicity. Int J Pharm. 2010;390(1):45-52.
25. Guo C, Gemeinhart RA. Understanding the adsorption mechanism of chitosan onto poly(lactide-co-glycolide) particles. Eur J Pharm Biopharm. 2008;70(2):597-604.
26. Harush-Frenkel O, Rozentur E, Benita S, Altschuler Y. Surface charge of nanoparticles determines their endocytic and transcytotic pathway in polarized MDCK cells. Biomacromolecules. 2008;9(2):435-443.
27. Irvine JD, Takahashi L, Lockhart K, et al. MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J Pharm Sci. 1999;88(1):28-33.
28. Fujiwara T, Akita H, Harashima H. Intracellular fate of octaarginine-modified liposomes in polarized MDCK cells. Int J Pharm. 2010; 386(1-2):122-130.
29. Win KY, Feng SS. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005;26(15):2713-2722.
30. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J. 2004;377(Pt 1):159-169.
31. Khalil IA, Kogure K, Futaki S, Harashima H. High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J Biol Chem. 2006;281(6): 3544-3551.
32. Dyer AM, Hinchcliffe M, Watts P, et al. Nasal delivery of insulin using novel chitosan based formulations: a comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharm Res. 2002;19(7):998-1008.
33. Won YW, Lim KS, Kim YH. Intracellular organelle-targeted non-viral gene delivery systems. J Control Release. 2011;152(1):99-109.
34. Benfer M, Kissel T. Cellular uptake mechanism and knockdown activity of siRNA-loaded biodegradable DEAPA-PVA-g-PLGA nanoparticles. Eur J Pharm Biopharm. 2012;80(2):247-256.
35. Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release. 2010;145(3):182-195.
36. Reix N, Parat A, Seyfritz E, et al. In vitro uptake evaluation in Caco-2 cells and in vivo results in diabetic rats of insulin-loaded PLGA nanoparticles. Int J Pharm. 2012;437(1-2):213-220.
37. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 2002;16(10): 1217-1226.
38. Bakhru SH, Altiok E, Highley C, et al. Enhanced cellular uptake and long-term retention of chitosan-modified iron-oxide nanoparticles for MRI-based cell tracking. Int J Nanomedicine. 2012;7:4613-4623.